Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
11:38am, Tuesday, 02'nd Jul 2024
The President of the United States, Joe Biden, and Sen. Bernie Sanders, the Senate Chairman of the Health, Education, Labor, and Pensions Committee, have long been vocal about the exorbitant prices th
How To Pick Top Pharma Stocks: Novo Nordisk And More
11:20am, Tuesday, 02'nd Jul 2024
This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various f
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
10:06am, Tuesday, 02'nd Jul 2024
Novo Nordisk stock fell Tuesday after Joe Biden and Bernie Sanders slammed the drugmaker and Eli Lilly for high prices of weight-loss drugs.
Novo Nordisk must cut prices of weight-loss drug, Biden says in USA Today piece
08:24am, Tuesday, 02'nd Jul 2024
U.S. President Joe Biden and Senator Bernie Sanders called on Novo Nordisk to cut prices of its Ozempic and Wegovy drugs for weight loss and diabetes, in an opinion piece by them published in USA Toda
Novo Nordisk steps up ad spend to keep the weight-loss crown
06:34am, Tuesday, 02'nd Jul 2024
Novo Nordisk (NYSE:NVO) appears to be taking a no-holds-barred approach to becoming the number one weight-loss drug in the US after it emerged that an ad for one of its key products was viewed nearly
3 Breakout Biotech Stocks on Track to Double by 2032
10:02am, Monday, 01'st Jul 2024
With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful
Novo Nordisk A/S - share repurchase programme
09:19am, Monday, 01'st Jul 2024
Bagsværd, Denmark, 01 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
09:15am, Sunday, 30'th Jun 2024
Novo Nordisk's flagship obesity care treatment, Wegovy, recently received approval in China. Obesity is a big medical issue in China, estimated to affect hundreds of millions of people.
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
06:00am, Friday, 28'th Jun 2024
Weight loss drugs have taken the pharmaceutical and medical communities by storm. Not only are the companies behind the medications struggling to keep up with global demand, but reports are emerging t
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
06:51pm, Thursday, 27'th Jun 2024
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $144.49, denoting a +0.57% change from the preceding trading day.
3 Biotech Stocks For The Second Half Of 2024
04:48pm, Thursday, 27'th Jun 2024
3 Biotech Stocks For The Second Half Of 2024
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
11:25am, Thursday, 27'th Jun 2024
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
Eli Lilly and Novo Nordisk are ahead in manufacturing but need time to meet demand, says Louise Chen
08:06am, Thursday, 27'th Jun 2024
Louise Chen, Cantor Fitzgerald analyst, joins CNBC's 'Squawk Box' to discuss Eli Lilly's surge over the past year, manufacturing, and more.
Healthcare: Best strategies to invest in pharma stocks
11:55am, Wednesday, 26'th Jun 2024
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names
Novo Nordisk makes impairment loss of $816 mln in Q2
10:58am, Wednesday, 26'th Jun 2024
Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to m
